Adaptive Biotechnologies Corporation (ADPT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ADPT SEC filings page.
Adaptive Biotechnologies Corporation (ADPT) reported $308.1M in revenue over the twelve months to Jun 30, 2026, up 50.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Scale and lower operating costs are narrowing losses, but the model still converts revenue into negative operating cash flow.
The margin step-up reflects more than added volume: gross margin reached74.2% while operating margin improved to-20.6% , showing that a larger share of each revenue dollar is reaching operations. Cash conversion remains incomplete: operating cash flow was-$46.0M against free cash flow of-$49.0M , so reduced losses have not yet become internally generated cash.
The balance-sheet posture is less strained than the income statement: current ratio was 3.3x and debt-to-equity was 0.6x, while total liabilities fell from the prior year and equity rose. That combination suggests the company is not relying on a heavily debt-funded structure to absorb operating losses, though accumulated losses remain embedded in equity.
R&D-led spending still defines the cost base: research and development was
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Adaptive Biotechnologies Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Adaptive Biotechnologies Corporation held $240.2M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $46.0M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Adaptive Biotechnologies Corporation scores 70/100 among other emerging companies.
Adaptive Biotechnologies Corporation had 154M shares outstanding at the end of fiscal year 2025, against 149M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Adaptive Biotechnologies Corporation scores 61/100 among other emerging companies.
Adaptive Biotechnologies Corporation spent $93.8M on research and development in fiscal year 2025, which was 28.1% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Adaptive Biotechnologies Corporation scores 61/100 among other emerging companies.
Adaptive Biotechnologies Corporation reported revenue of $277.0M in fiscal year 2025, against $179.0M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Adaptive Biotechnologies Corporation scores 70/100 among other emerging companies.
Adaptive Biotechnologies Corporation's operations used $46.0M of cash in fiscal year 2025, against $95.2M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Adaptive Biotechnologies Corporation scores 80/100 among other emerging companies.
Adaptive Biotechnologies Corporation's cash, cash equivalents and investments came to $240.2M at the end of fiscal year 2025, against $287.7M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Adaptive Biotechnologies Corporation scores 54/100 among other emerging companies.
Adaptive Biotechnologies Corporation scores 5.00, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($3.9B) relative to total liabilities ($287.7M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Adaptive Biotechnologies Corporation passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Adaptive Biotechnologies Corporation reported a net loss of $59.5M while operations used $46.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Adaptive Biotechnologies Corporation reported an operating loss of $57.1M against $11.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Adaptive Biotechnologies Corporation generated $71.6M in revenue in Q2 2026. This represents an increase of 21.5% from the same quarter a year earlier. Against the prior quarter it is up 1.0%.
Adaptive Biotechnologies Corporation reported -$39.8M in net income in Q2 2026. This represents a decrease of 55.3% from the same quarter a year earlier. Against the prior quarter it is down 98.6%.
Adaptive Biotechnologies Corporation earned -$0.25 per diluted share (EPS) in Q2 2026. This represents a decrease of 47.1% from the same quarter a year earlier. Against the prior quarter it is down 92.3%.
Not reported for Q2 2026.
Cash & Balance Sheet
Adaptive Biotechnologies Corporation recorded an outflow of $7.6M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 42.0% from the same quarter a year earlier. Against the prior quarter it is up 26.6%.
Adaptive Biotechnologies Corporation held $169.9M in cash against $0 in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Adaptive Biotechnologies Corporation's gross margin was 71.8% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.8 percentage points.
Adaptive Biotechnologies Corporation's operating margin was -22.0% in Q2 2026, reflecting core business profitability. This is up 20.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.1 percentage points.
Adaptive Biotechnologies Corporation's net profit margin was -55.6% in Q2 2026, showing the share of revenue converted to profit. This is down 12.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 27.3 percentage points.
Adaptive Biotechnologies Corporation's ROE was -27.8% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 13.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 18.6 percentage points.
Capital Allocation
Adaptive Biotechnologies Corporation invested $19.2M in research and development in Q2 2026. This represents a decrease of 20.6% from the same quarter a year earlier. Against the prior quarter it is down 18.9%.
Adaptive Biotechnologies Corporation invested $1.2M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 80.8% from the same quarter a year earlier. Against the prior quarter it is up 48.7%.
Not reported for Q2 2026.
ADPT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $71.6M+21.5% | $70.9M+35.1% | $71.7M+51.0% | $94.0M+102.4% | $58.9M+36.3% | $52.4M+25.2% | $47.5M+3.7% | $46.4M+22.5% |
| Cost of Revenue | $20.2M+12.0% | $18.7M+10.2% | $18.2M+1.0% | $18.2M+8.9% | $18.0M-6.8% | $17.0M-5.9% | $18.0M-8.0% | $16.7M-13.8% |
| Gross Profit | $51.4M+25.7% | $52.2M+47.1% | $53.5M+81.7% | $75.8M+154.7% | $40.9M+71.2% | $35.5M+48.9% | $29.4M+12.4% | $29.8M+60.3% |
| R&D Expenses | $19.2M-20.6% | $23.6M-2.4% | $21.8M-6.2% | $23.7M-2.0% | $24.1M-4.8% | $24.2M-20.0% | $23.2M-19.3% | $24.2M-15.3% |
| SG&A Expenses | $21.2M+19.0% | $21.0M+20.6% | $19.6M+8.3% | $18.0M+4.1% | $17.8M-0.6% | $17.4M-11.2% | $18.1M-12.9% | $17.3M-14.0% |
| Operating Income | -$15.8M+37.0% | -$19.2M+35.1% | -$12.8M+62.3% | $10.3M+131.5% | -$25.0M+47.1% | -$29.6M+39.3% | -$33.8M+52.4% | -$32.6M+36.0% |
| EBITDA | N/A | -$15.8M+37.5% | -$9.1M+70.0% | $14.3M+150.1% | -$21.0M+51.0% | -$25.3M+41.9% | -$30.3M+55.6% | -$28.5M+37.0% |
| Interest Expense | $2.7M-8.6% | $2.9M-0.6% | $3.0M+0.1% | $3.0M+1.1% | $2.9M+9.3% | $2.9M-2.9% | $3.0M-2.0% | $2.9M-19.5% |
| Net Income | -$39.8M-55.3% | -$20.0M+32.9% | -$13.6M+59.7% | $9.5M+129.8% | -$25.6M+44.6% | -$29.9M+37.2% | -$33.7M+51.5% | -$32.1M+36.2% |
| EPS (Basic) | -$0.25-47.1% | -$0.13+35.0% | -$0.09+59.1% | $0.06+127.3% | -$0.17+45.2% | -$0.20+39.4% | -$0.22+54.2% | -$0.22+37.1% |
| EPS (Diluted) | -$0.25-47.1% | -$0.13+35.0% | -$0.09+59.1% | $0.06+127.3% | -$0.17+45.2% | -$0.20+39.4% | -$0.22+54.2% | -$0.22+37.1% |
| Diluted Shares (Avg) | 160M+5.1% | 156M+4.2% | N/A | 163M+10.6% | 152M+3.2% | 149M+2.3% | N/A | 148M+1.9% |
Not reported in any period shown, so not listed: Income Tax.
ADPT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $640.7M+29.0% | $505.9M-1.0% | $512.7M-4.9% | $490.6M-12.2% | $496.6M-15.1% | $510.9M-17.6% | $539.4M-18.4% | $558.5M-22.2% |
| Current Assets | $420.6M+60.6% | $291.8M+13.8% | $300.2M+5.8% | $281.4M-8.7% | $261.9M-25.5% | $256.5M-31.4% | $283.8M-30.8% | $308.3M-29.2% |
| Cash & Equivalents | $169.9M+293.6% | $77.6M+53.2% | $70.5M+47.1% | $55.0M+44.5% | $43.2M-27.9% | $50.6M-28.9% | $47.9M-26.3% | $38.1M-57.1% |
| Short-Term Investments | $174.4M+12.7% | $140.8M-1.4% | $156.5M-10.3% | $157.7M-23.1% | $154.7M-33.3% | $142.8M-39.9% | $174.4M-38.0% | $205.2M-27.3% |
| Inventory | $10.5M+24.9% | $11.2M+29.0% | $9.8M+16.4% | $9.9M-16.9% | $8.4M-36.4% | $8.7M-34.7% | $8.4M-41.6% | $12.0M-38.7% |
| Accounts Receivable | $49.5M+11.8% | $48.3M+10.9% | $50.4M+20.7% | $44.8M+9.8% | $44.3M+24.4% | $43.6M+3.7% | $41.7M+9.9% | $40.8M+30.8% |
| Long-Term Investments | $27.5M+14.0% | $18.9M-52.0% | $13.2M-60.7% | $4.0M-83.1% | $24.1M | $39.4M | $33.7M | $23.9M |
| Goodwill | $119.0M0.0% | $119.0M0.0% | $119.0M0.0% | $119.0M0.0% | $119.0M0.0% | $119.0M0.0% | $119.0M0.0% | $119.0M0.0% |
| Total Liabilities | $490.0M+54.5% | $281.7M-12.1% | $287.7M-14.6% | $286.4M-14.5% | $317.1M-7.7% | $320.6M-7.2% | $336.9M-4.5% | $334.9M-5.9% |
| Current Liabilities | $87.7M-4.8% | $87.0M-0.9% | $89.9M-8.3% | $83.4M-4.9% | $92.1M+4.6% | $87.8M+5.9% | $98.1M+11.4% | $87.6M-6.1% |
| Non-Current Liabilities | $402.3M+78.8% | $194.7M-16.4% | $197.8M-17.2% | $203.0M-17.9% | $225.0M-11.9% | $232.8M-11.3% | $238.8M-9.8% | $247.3M-5.9% |
| Long-Term Debt | $0-100.0% | $124.7M-5.2% | $126.6M-4.4% | $129.4M-2.5% | $130.5M-1.2% | $131.6M0.0% | $132.4M+1.3% | $132.7M+4.7% |
| Total Equity | $142.9M-20.5% | $216.3M+13.6% | $218.8M+7.9% | $204.4M-8.6% | $179.7M-25.6% | $190.4M-30.7% | $202.7M-34.3% | $223.8M-38.1% |
| Retained Earnings | -$1.4B-4.7% | -$1.4B-3.7% | -$1.4B-4.6% | -$1.3B-6.3% | -$1.4B-9.8% | -$1.3B-11.9% | -$1.3B-13.9% | -$1.3B-18.2% |
ADPT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$6.4M+48.5% | -$9.5M+66.5% | $2.1M+116.5% | -$7.1M+73.7% | -$12.4M+28.2% | -$28.5M+25.7% | -$12.5M+53.6% | -$27.1M+42.0% |
| Depreciation & Amortization | N/A | $3.4M-21.0% | $3.7M-7.1% | $4.0M-4.4% | $4.1M-10.9% | $4.3M-17.8% | $3.9M+42.4% | $4.2M-27.9% |
| Stock-Based Compensation | $11.1M-16.8% | $11.9M-1.8% | N/A | $13.3M-2.0% | $13.4M+3.1% | $12.1M-15.0% | N/A | $13.5M-11.8% |
| Capital Expenditures | $1.2M+80.8% | $796K-36.8% | $636K+695.0% | $409K+18.9% | $655K-62.1% | $1.3M-16.7% | $80K-93.8% | $344K-87.6% |
| Free Cash Flow | -$7.6M+42.0% | -$10.3M+65.3% | $1.4M+111.3% | -$7.5M+72.5% | -$13.1M+31.2% | -$29.7M+25.4% | -$12.6M+55.5% | -$27.4M+44.6% |
| Investing Cash Flow | -$43.5M-1399.4% | $9.1M-64.2% | -$8.3M-137.3% | $17.3M+226.9% | $3.3M-43.1% | $25.6M-42.5% | $22.1M+589.7% | $5.3M-79.8% |
| Financing Cash Flow | $142.2M+8731.6% | $7.5M+37.6% | $21.7M+16953.5% | $1.7M+4110.0% | $1.6M+5266.7% | $5.5M+12288.6% | $127K+46.0% | $40K+135.3% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ADPT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 71.8%+2.4pp | 73.6%+6.0pp | 74.6%+12.6pp | 80.7%+16.6pp | 69.4%+14.2pp | 67.6%+10.7pp | 62.0%+4.8pp | 64.1%+15.1pp |
| Operating Margin | -22.0%+20.5pp | -27.1%+29.3pp | -17.8%+53.5pp | 10.9%+81.2pp | -42.5% | -56.5% | -71.3% | -70.3% |
| Net Margin | -55.6%-12.1pp | -28.3%+28.7pp | -18.9%+52.0pp | 10.2%+79.2pp | -43.5% | -56.9% | -71.0% | -69.1% |
| Return on Equity | -27.8%-13.6pp | -9.3%+6.4pp | -6.2%+10.4pp | 4.7%+19.0pp | -14.2%+4.9pp | -15.7%+1.6pp | -16.6%+5.9pp | -14.3%-0.4pp |
| Return on Assets | -6.2%-1.1pp | -4.0%+1.9pp | -2.6%+3.6pp | 1.9%+7.7pp | -5.2%+2.7pp | -5.8%+1.8pp | -6.3%+4.3pp | -5.7%+1.3pp |
| Current Ratio | 4.79+2.0x | 3.35+0.4x | 3.34+0.4x | 3.38-0.1x | 2.84-1.1x | 2.92-1.6x | 2.89-1.8x | 3.52-1.1x |
| Debt-to-Equity | 0.00-0.7x | 0.58-0.1x | 0.58-0.1x | 0.630.0x | 0.73+0.2x | 0.69+0.2x | 0.65+0.2x | 0.59+0.2x |
| Asset Turnover | 0.110.0x | 0.140.0x | 0.14+0.1x | 0.19+0.1x | 0.120.0x | 0.100.0x | 0.090.0x | 0.080.0x |
| FCF Margin | -10.6%+11.6pp | -14.6%+42.1pp | 2.0%+28.5pp | -8.0%+51.0pp | -22.2%+21.8pp | -56.7%+38.5pp | -26.5%+35.2pp | -59.0% |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Adaptive Biotechnologies Corporation ADPT | FY2025 | $277.0M | -$59.5M | -21.5% | $3.9B | 66/100 |
| Agios Pharmaceuticals, Inc. AGIO | FY2025 | $54.0M | -$413.0M | N/A | $2.0B | 70/100 |
| Travere Therapeutics, Inc. TVTX | FY2025 | $490.7M | -$25.5M | -5.2% | $6.2B | 70/100 |
| Tarsus Pharmaceuticals, Inc. TARS | FY2025 | $451.4M | -$66.0M | -14.6% | $3.7B | 49/100 |
| IDEAYA Biosciences, Inc. IDYA | FY2025 | $218.7M | -$113.7M | -52.0% | $3.6B | 84/100 |
Where Adaptive Biotechnologies Corporation Ranks
Frequently Asked Questions
What is Adaptive Biotechnologies Corporation's annual revenue?
Adaptive Biotechnologies Corporation (ADPT) reported $277.0M in total revenue for fiscal year 2025. This represents a 54.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Adaptive Biotechnologies Corporation's revenue growing?
Adaptive Biotechnologies Corporation (ADPT) revenue grew by 54.8% year-over-year, from $179.0M to $277.0M in fiscal year 2025.
Is Adaptive Biotechnologies Corporation profitable?
No, Adaptive Biotechnologies Corporation (ADPT) reported a net income of -$59.5M in fiscal year 2025, with a net profit margin of -21.5%.
What is Adaptive Biotechnologies Corporation's EBITDA?
Adaptive Biotechnologies Corporation (ADPT) had EBITDA of -$41.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Adaptive Biotechnologies Corporation have?
As of fiscal year 2025, Adaptive Biotechnologies Corporation (ADPT) had $70.5M in cash and equivalents against $126.6M in long-term debt.
What is Adaptive Biotechnologies Corporation's gross margin?
Adaptive Biotechnologies Corporation (ADPT) had a gross margin of 74.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Adaptive Biotechnologies Corporation's operating margin?
Adaptive Biotechnologies Corporation (ADPT) had an operating margin of -20.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Adaptive Biotechnologies Corporation's net profit margin?
Adaptive Biotechnologies Corporation (ADPT) had a net profit margin of -21.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Adaptive Biotechnologies Corporation's return on equity (ROE)?
Adaptive Biotechnologies Corporation (ADPT) has a return on equity of -27.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Adaptive Biotechnologies Corporation's free cash flow?
Adaptive Biotechnologies Corporation (ADPT) recorded an outflow of $48.9M in free cash flow during fiscal year 2025. This represents a 50.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Adaptive Biotechnologies Corporation's operating cash flow?
Adaptive Biotechnologies Corporation (ADPT) recorded an outflow of $46.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Adaptive Biotechnologies Corporation's total assets?
Adaptive Biotechnologies Corporation (ADPT) had $512.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Adaptive Biotechnologies Corporation's capital expenditures?
Adaptive Biotechnologies Corporation (ADPT) invested $3.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Adaptive Biotechnologies Corporation spend on research and development?
Adaptive Biotechnologies Corporation (ADPT) invested $93.8M in research and development during fiscal year 2025.
What is Adaptive Biotechnologies Corporation's current ratio?
Adaptive Biotechnologies Corporation (ADPT) had a current ratio of 3.34 as of fiscal year 2025, which is generally considered healthy.
What is Adaptive Biotechnologies Corporation's debt-to-equity ratio?
Adaptive Biotechnologies Corporation (ADPT) had a debt-to-equity ratio of 0.58 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Adaptive Biotechnologies Corporation's return on assets (ROA)?
Adaptive Biotechnologies Corporation (ADPT) had a return on assets of -11.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Adaptive Biotechnologies Corporation's P/E ratio?
Adaptive Biotechnologies Corporation (ADPT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $3.9B as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Adaptive Biotechnologies Corporation's price-to-sales ratio?
Adaptive Biotechnologies Corporation (ADPT) trades at 12.5x sales, its market capitalization divided by revenue of $308.1M revenue, trailing 12 months to June 30, 2026. The market capitalization is $3.9B as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Adaptive Biotechnologies Corporation's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Adaptive Biotechnologies Corporation (ADPT) held $240.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $46.0M over that year. Dividing the one by the other, the reported balance equals about 63 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Adaptive Biotechnologies Corporation's Altman Z-Score?
Adaptive Biotechnologies Corporation (ADPT) has an Altman Z-Score of 5.00, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Adaptive Biotechnologies Corporation's Piotroski F-Score?
Adaptive Biotechnologies Corporation (ADPT) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Adaptive Biotechnologies Corporation's earnings high quality?
Adaptive Biotechnologies Corporation (ADPT) reported a net loss of $59.5M while operations used $46.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Adaptive Biotechnologies Corporation cover its interest payments?
Adaptive Biotechnologies Corporation (ADPT) reported an operating loss of $57.1M against $11.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Adaptive Biotechnologies Corporation?
Adaptive Biotechnologies Corporation (ADPT) scores 66 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.